Abstract
Formaldehyde treatment is a process widely used in vaccine preparation to inactivate bacterial toxins such as diphtheria and tetanus (Rappuoli, 1990). Formaldehyde-inactivated bacterial toxins have been proven to be efficacious as vaccines; however, the chemical modification of a protein can affect its immunogenicity by altering B and T cell epitopes. A more rational approach for bacterial toxin inactivation is the use of recombinant DNA technology. The advantages of this approach are:i) maintainance of the native protein conformation and therefore of the original epitopes; ii) no risk of reversion to toxicity; iii) consistency in vaccine production. We therefore used this approach for the development of a new vaccine against pertussis.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
De Magistris, M.T., Romano, M., Nuti, S., Rappuoli, R. and Tagliabue, A., 1988, Dissecting human T cell responses againstBordetellaspecies,J.Exp.Med., 168:1351
De Magistris, M.T., Romano, M., Bartoloni, A., Rappuoli, R. and Tagliabue, A., 1989, Human T cell clones define SI subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map,J.Exp.Med., 169:1519
De Magistris, M.T., Di Tommaso, A., Domenighini, M., Censini, S., Tagliabue, A., Oksenberg, J.R., Steinman, L., Judd, A.K. and Rappuoli, R., 1992, Interaction of the pertussis toxin peptide containing residues 30–42 with DR1 and the T cell receptors of 12 human T cell clones,Proc.Natl.Acad.Sci.USA, 89:2990
Di Tommaso, A., De Magistris, M.T., Bugnoli, M., Marsili, I., Rappuoli, R. and Abrignani, S., 1994, Formaldehyde treatment of protein can constrain presentation to T cells by limiting antigen processing,Infect.Immun., 62:1830
Friedman, R., 1988, Pertussis:the disease and new diagnostic methods,Clin.Microbiol.Rev., 1:365
Hewlett, E.L. and Weiss, A., 1986, Virulence factors ofBordetella pertussis,Ann.Rev.Microbiol., 40:661
Moxon, R., Rappuoli, R., 1990, Modern vaccines:Haemophilus influenzae infections and whooping cough,Lancet, i: 1324
Nencioni, L., Pizza, M., Bugnoli, M., De Magistris, M.T., Di Tommaso, A., Giovannoni, F., Manetti, R., Marsili, I., Matteucci, G., Nucci, D., Olivieri, R., Pileri, P., Presentini, R., Villa, L, Kreeftenberg, J.G., Silvestri, S., Tagliabue, A. and Rappuoli, R., 1990, Characterization of genetically inactivated pertussis toxin mutants:candidates for a new vaccine against whooping cough,Infect.Immun., 58:1308
Nencioni, L., Volpini, G., Peppoloni, S. De Magistris, M.T., Marsili, I. and Rappuoli, R., 1991, Properties of the pertussis toxin mutant PT-9K/129G after formaldehyde treatment,Infect.Immun., 59:625
Pittman, M., 1984, The concept of pertussis as a toxin-mediated disease,Pediatric Infect.Dis., 3:467
Pizza, M., Covacci, A., Bartoloni, A., Perugini, M., Nencioni, L., De Magistris, M.T., Villa, L., Nucci, D., Manetti, R., Bugnoli, M., Giovannoni, F., Olivieri, R., Barbieri, J.T., Sato, H. and Rappuoli, R., 1989, Mutants of pertussis toxin suitable for vaccine development,Science, 246:497
Podda, A., Nencioni, L., De Magistris, M.T., Di Tommaso, A., Bossú, P., Nuti, S., Pileri, P., Peppoloni, S., Bugnoli, M., Ruggiero, P., Marsili, L, D’Errico, A., Tagliabue, A. and Rappuoli, R., 1990, Metabolic, humoral, and cellular responses in adult volunteers immunised with the genetically inactivated pertussis toxin mutant PT9K/129G,J.Exp.Med., 172:861
Podda, A., Nencioni, L., Marsili, I., Peppoloni, S., Volpini, G., Donati, D., Di Tommaso, A., De Magistris, M.T. and Rappuoli, R., 1991, Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69K,Vaccine, 9:741
Podda, A., Carapella-De Luca, E., Titone, L., Casadei, A.M., Cascio, A., Peppoloni, S., Volpini, G., Marsili, I., Nencioni, L. and Rappuoli, R., 1992, Acellular pertussis vaccine composed of genetically inactivated pertussis toxin:safety and immunogenicity in 12- to 24- and 2- to 4 month-old children,J.Pediatrics, 120:680
Podda, A., Carapella-De Luca, E., Titone, L., Casadei, A.M., Cascio, A., Bartalini, M., Volpini, G., Peppoloni, S., Marsili, I., Nencioni, L. and Rappuoli, R., 1993, Immunogenicity of an acellular vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children,J.Pediatrics, 123:81
Podda, A., Carapella-De Luca, E., Contu, B., Furlan, R., Maida, A., Moiraghi, A., Stramare, D., Titone, L., Uxa, F., Di Pisa, F., Peppoloni, S., Nencioni, L., Rappuoli, R., the Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine, 1994, Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine, J.Pediatrics, 124:921
Rappuoli, R., 1990, New and improved vaccines against diphtheria and tetanus,in: G.C. Woodrow, M.M. Levine (eds), New generation vaccines, Marcel Dekker, Inc., New York
Storsaeter, J., Olin, P., Renemar, B., Lagergard, T., Norberg, R., Romanus, V. and Tiru, M., 1988, Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden,Pediatr.Infect.Dis.J., 7:637
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
De Magistris, M.T., >Di Tommaso, A., Pizza, M., Rappuoli, R. (1995). Rational Design of Vaccine Molecules to Prevent Pertussis. In: Gregoriadis, G., McCormack, B., Allison, A.C. (eds) Vaccines. Nato Science Series, vol 282. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0357-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0357-2_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8014-6
Online ISBN: 978-1-4613-0357-2
eBook Packages: Springer Book Archive